Overcoming psychological barriers to good discovery decisions

Drug Discovery Today

Volumn 15, Issue 13-14, 2010, Pages 561-569

  Chadwick, Andrew T ^a   Segall, Matthew D ^b  

^a Stanhope Bretby ^*  (United Kingdom)

^b OPTIBRIUM LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COGNITION; DECISION MAKING; DRUG RESEARCH; EVIDENCE BASED MEDICINE; PSYCHOLOGICAL ASPECT; REVIEW;

ANIMALS; BIOMEDICAL RESEARCH; COMPUTATIONAL BIOLOGY; DECISION MAKING, ORGANIZATIONAL; DECISION SUPPORT SYSTEMS, MANAGEMENT; DRUG DISCOVERY; EFFICIENCY, ORGANIZATIONAL; EVIDENCE-BASED MEDICINE; HUMANS; PROBLEM SOLVING; PSYCHOLOGY, INDUSTRIAL;

EID: 77954316269     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.05.007     Document Type: Review

References (42)

1. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 2009, 8:959-968.
2. Paul S.M., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010, 9:203-214.
3. Bernal L. Why pharma must go Hollywood. Scientist 2007, 21:42.
4. Andersson S., et al. Making medicinal chemistry more effective - application of Lean Sigma to improve processes, speed and quality. Drug Discov. Today 2009, 14:598-604.
5. Tushman M.L., Benner M. The productivity dilemma revisited: inherent conflicts between process management and exploration. In Adler, P.S et al Perspectives on the Productivity Dilemma. J. Ops Manage. 2009, 27:99-113.
6. Baron J. Thinking and Deciding 2000, Cambridge University Press. 3rd edn.
7. Peck R.W. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Drug Discov. Today 2007, 12:289-294.
8. Hammond J.S., et al. The hidden traps in decision making. Harv. Bus. Rev. 1998, 76:47-50.
9. Russo J.E., Schoemaker P.J.H. Winning Decisions: Getting it Right the First Time 2002, Doubleday.
10. Evans J.St.B.T. Bias in human reasoning: causes and consequences. Essays in Cognitive Psychology 1990, Lawrence Erlbaum Associates.
11. Segall M.D. Why is it still drug discovery?. Eur. Biopharmaceut. Rev. 2008, Spring issue.
12. Cuatrecasas P. Drug discovery in jeopardy. J. Clin. Invest. 2006, 116:2837-2842.
13. Sutherland S. Irrationality 2007, Pinter and Martin.
14. Goldacre, B. (2008) Bad Science, Fourth Estate, additional chapter available free of charge through http://www.amazon.co.uk/Bad-Science-Ben-Goldacre/dp/000728487X/?tag=bs0b-21.
15. Kahneman D., Lovallo D. Timid choices and bold forecasts: a cognitive perspective on risk taking. Manage. Sci. 1993, 39:17-31.
16. Seligman M.E.P., et al. Positive psychotherapy. Am. Psychol. 2006, 61:774-788.
17. Segall M.D., et al. Focus on success: using in silico optimisation to achieve an optimal balance of properties. Expert Opin. Drug Metab. Toxicol. 2006, 2:325-337.
18. Graber M.L., et al. Diagnostic error in internal medicine. Arch. Intern. Med. 2005, 165:1493-1499.
19. Baron J. Thinking and Deciding 2000, Cambridge University Press, pp. 127. 3rd edn.
20. Bonabeau E., et al. A more rational approach to new-product development. Harv. Bus. Rev. 2008, 86:96-102.
21. Feuerstein G.Z., Chavez J. Translational medicine for stroke drug discovery: the pharmaceutical industry perspective. Stroke 2009, 40:S121-S125.
22. Gladstone D.J., et al. Toward wisdom from failure: lessons learned from neuroprotective stroke trials and new therapeutic directions. Stroke 2002, 33:2123-2136.
23. Sena E.S., et al. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol. 2010, 8:e1000344.
24. Feuerstein G.Z., et al. Missing steps in the STAIR case: a translational medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J. Cereb. Blood Flow Metab. 2008, 28:217-219.
25. Grotta J. Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke 2002, 33:306-307.
26. Elstein A.S., Schwarz A. Clinical problem solving and diagnostic decision making: selective review of the cognitive literature. BMJ 2002, 324:729-732.
27. Bradley C.P. Can we avoid bias?. BMJ 2005, 330:784.
28. Esserman L., et al. Improving the accuracy of mammography: volume and outcome relationships. J. Natl. Cancer Inst. 2002, 94:369-375.
29. Goodwin P., Wright G. Decision Analysis for Management Judgment 2004, Wiley, pp. 270. 3rd edn.
30. Gonzalez C., Brunstein A. Training for emergencies. J. Trauma 2009, 67:S100-S105.
31. The answer is (c), approximately 10%. Of 1000 compounds, 108 (990×0.1+10×0.9) would be reported as toxic by the test, of which only 9 really are toxic.
32. Gigerenzer G., Edwards A. Simple tools for understanding risks: from innumeracy to insight. BMJ 2003, 327:741-744.
33. DeWitte R.S. On experimental design in drug discovery. Curr. Drug Disc. 2002, 2:19-22.
34. Hardman D. Judgment and Decision Making: Psychological Perspectives 2009, BPS Blackwell, (Chapter 7).
35. Goodwin P., Wright G. Decision Analysis for Management Judgment 2004, Wiley, pp. 449-451. 3rd edn.
36. Gittins J. Quantitative methods in the planning of pharmaceutical research. Drug Inf. J. 1996, 30:479-487.
37. Segall M., et al. Beyond profiling: using ADMET models to guide decisions. Chem. Biodivers. 2009, 6:2144-2151.
38. Segall M.D., et al. Guiding the decision-making process to identify high quality compounds. Drug Metab. Rev. 2009, 41(s3):7-186. (Abstract 244).
39. Ades A.E., et al. Multiparameter evidence synthesis in epidemiology and medical decision making. J. Health Serv. Res. Policy 2008, 13:12-22.
40. Chadwick A.T., Edwards R.A. Smart planner: radically accelerating R&D to combat a biothreat. Drug Dev. Res. 2009, 70:335-348.
41. Sim I., et al. Evidence-based practice for mere mortals: the role of informatics and health services research. J. Gen. Intern. Med. 2002, 17:302-308.
42. Wason P.C. On the failure to eliminate hypotheses in a conceptual task. Q. J. Exp. Psychol. 1960, 12:129-140.